Barclays lowered the firm’s price target on PTC Therapeutics (PTCT) to $42 from $56 and keeps an Equal Weight rating on the shares following the Q1 beat.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics’ Earnings Call: Strong Start to 2025
- Biotech Alert: Searches spiking for these stocks today
- PTC Therapeutics price target lowered to $66 from $70 at Baird
- PTC Therapeutics: Strong Revenue Performance and Promising Pipeline Present Compelling Buy Opportunity
- PTC Therapeutics price target lowered to $67 from $75 at JPMorgan